Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care
Daxor (Nasdaq: DXR) has announced the expansion of its blood volume analysis (BVA) capabilities through its ezBVA Lab service. The company is partnering with a leading 1,000+ bed comprehensive medical center in western Florida to provide lab processing of patient tests, offering a rapid 24-hour testing service. This implementation aims to optimize heart failure treatment outcomes, improve patient and clinical experiences, and reduce associated costs.
The BVA-100™ Blood Volume Diagnostic facilitates optimal diagnosis of patient volume status, which is important for both in-patient and out-patient heart failure care. Daxor's CEO, Michael Feldschuh, emphasized that their BVA diagnostic delivers 98% accurate, actionable data to guide individualized fluid management, enhancing patient outcomes and optimizing costs. The ezBVA Lab service is reimbursed by both public and private insurance in inpatient and outpatient care using established CPT codes.
Daxor (Nasdaq: DXR) ha annunciato l'espansione delle sue capacità di analisi del volume sanguigno (BVA) attraverso il suo servizio ezBVA Lab. L'azienda sta collaborando con un importante centro medico completo con oltre 1.000 posti letto nella Florida occidentale per fornire l'elaborazione in laboratorio dei test dei pazienti, offrendo un servizio di test rapido in 24 ore. Questa implementazione mira a ottimizzare i risultati del trattamento per l'insufficienza cardiaca, migliorare l'esperienza dei pazienti e clinica, e ridurre i costi associati.
Il BVA-100™ Blood Volume Diagnostic facilita una diagnosi ottimale dello stato del volume del paziente, importante per la cura dell'insufficienza cardiaca sia in ricovero che in ambulatorio. Il CEO di Daxor, Michael Feldschuh, ha sottolineato che il loro diagnostico BVA fornisce dati accurati e utilizzabili al 98% per guidare una gestione fluidica personalizzata, migliorando i risultati per i pazienti e ottimizzando i costi. Il servizio ezBVA Lab è rimborsato da assicurazioni pubbliche e private per la cura sia in ricovero che in ambulatorio utilizzando codici CPT consolidati.
Daxor (Nasdaq: DXR) ha anunciado la expansión de sus capacidades de análisis del volumen sanguíneo (BVA) a través de su servicio ezBVA Lab. La empresa se está asociando con un importante centro médico integral de más de 1,000 camas en el oeste de Florida para proporcionar el procesamiento de laboratorio de pruebas de pacientes, ofreciendo un servicio de pruebas rápidas en 24 horas. Esta implementación tiene como objetivo optimizar los resultados del tratamiento de la insuficiencia cardíaca, mejorar la experiencia de pacientes y clínicos, y reducir los costos asociados.
El BVA-100™ Blood Volume Diagnostic facilita un diagnóstico óptimo del estado del volumen del paciente, que es importante tanto para el cuidado de insuficiencia cardíaca hospitalaria como ambulatoria. El CEO de Daxor, Michael Feldschuh, destacó que su diagnóstico BVA proporciona datos precisos y utilizables al 98% para guiar la gestión personalizada de fluidos, mejorando los resultados del paciente y optimizando los costos. El servicio ezBVA Lab está cubierto por seguros públicos y privados en el cuidado hospitalario y ambulatorio utilizando códigos CPT establecidos.
Daxor (Nasdaq: DXR)는 ezBVA Lab 서비스를 통해 혈액량 분석(BVA) 기능을 확장한다고 발표했습니다. 이 회사는 플로리다 서부에 있는 1,000병상 이상의 종합 의료 센터와 협력하여 환자 테스트의 실험실 처리를 제공하며, 24시간 신속 검사 서비스를 제공합니다. 이러한 구현은 심부전 치료 성과 최적화, 환자와 임상 경험 개선, 관련 비용 절감을 목표로 하고 있습니다.
BVA-100™ 혈액량 진단기는 환자의 체액 상태를 최적의 방법으로 진단할 수 있게 해주며, 이는 입원 및 외래 심부전 치료 모두에서 중요합니다. Daxor의 CEO인 Michael Feldschuh는 BVA 진단이 개인화된 체액 관리를 안내하는 98% 정확하고 실행 가능한 데이터를 제공한다고 강조했습니다. ezBVA Lab 서비스는 확립된 CPT 코드를 사용하여 입원 및 외래 치료에 대해 공공 및 민간 보험으로 보장됩니다.
Daxor (Nasdaq: DXR) a annoncé l'expansion de ses capacités d'analyse du volume sanguin (BVA) à travers son service ezBVA Lab. La société s'associe à un important centre médical complet de plus de 1 000 lits dans l'ouest de la Floride pour fournir le traitement des tests des patients en laboratoire, offrant un service de test rapide de 24 heures. Cette mise en œuvre vise à optimiser les résultats du traitement de l'insuffisance cardiaque, à améliorer l'expérience des patients et des cliniciens, et à réduire les coûts associés.
Le BVA-100™ Blood Volume Diagnostic facilite un diagnostic optimal de l'état du volume des patients, ce qui est important pour les soins des insuffisances cardiaques en hospitalisation et en consultation externe. Le PDG de Daxor, Michael Feldschuh, a souligné que leur diagnostic BVA fournit des données précises et exploitables à 98% pour guider la gestion personnalisée des fluides, améliorant les résultats des patients et optimisant les coûts. Le service ezBVA Lab est remboursé par les assurances publiques et privées dans les soins hospitaliers et ambulatoires en utilisant des codes CPT établis.
Daxor (Nasdaq: DXR) hat die Erweiterung seiner Blutvolumenanalyse (BVA) Fähigkeiten durch seinen ezBVA Lab Service angekündigt. Das Unternehmen arbeitet mit einem führenden medizinischen Zentrum mit mehr als 1.000 Betten in West-Florida zusammen, um die Laborverarbeitung von Patiententests anzubieten und einen schnellen Testservice innerhalb von 24 Stunden bereitzustellen. Dieses Implementierungsziel ist es, die Ergebnisse der Herzinsuffizienzbehandlung zu optimieren, die Patienten- und klinische Erfahrung zu verbessern und die damit verbundenen Kosten zu senken.
Der BVA-100™ Blutvolumen-Diagnosetester erleichtert die optimale Diagnose des Volumenstatus des Patienten, was sowohl für stationäre als auch für ambulante Herzinsuffizienzpflege wichtig ist. Der CEO von Daxor, Michael Feldschuh, betonte, dass ihre BVA-Diagnostik 98% genaue, umsetzbare Daten liefert, um eine individualisierte Flüssigkeitsverwaltung zu steuern, und dadurch die Behandlungsergebnisse verbessert und Kosten optimiert. Der ezBVA Lab Service wird von sowohl öffentlichen als auch privaten Versicherungen bei stationärer und ambulanter Pflege unter Verwendung etablierter CPT-Codes erstattet.
- Partnership with a leading 1,000+ bed comprehensive medical center in Florida
- Expansion of blood volume analysis capabilities through ezBVA Lab service
- BVA-100™ diagnostic delivers 98% accurate, actionable data for heart failure care
- ezBVA Lab service reimbursed by both public and private insurance
- None.
Insights
The implementation of Daxor's BVA-100™ Blood Volume Diagnostic at a major Central Florida hospital marks a significant advancement in heart failure patient care. This 98% accurate diagnostic tool addresses a critical aspect of heart failure management - volume status. By providing precise data on blood volume, it enables personalized fluid management, which is important for optimizing treatment outcomes.
The ezBVA Lab service offers a cost-effective solution for hospitals to access this technology without significant capital investment. With both public and private insurance coverage for inpatient and outpatient care, this service could potentially improve accessibility to advanced diagnostics across various healthcare settings. The 24-hour turnaround time for test results also suggests improved efficiency in patient care workflows.
Daxor's expansion through the ezBVA Lab service represents a strategic move to increase market penetration. By partnering with a 1,000+ bed comprehensive medical center, Daxor gains access to a large patient population, potentially driving significant revenue growth. The service model eliminates the need for hospitals to make upfront capital investments, which could accelerate adoption rates.
The established CPT codes for reimbursement from both public and private insurers provide a stable revenue stream. This business model combines the benefits of recurring revenue with reduced customer acquisition costs, as hospitals can easily implement the service. However, investors should monitor the scalability of this service model and its impact on Daxor's profit margins compared to direct equipment sales.
The adoption of Daxor's BVA technology by a leading Florida hospital signifies a growing trend towards precision medicine in cardiac care. This move aligns with the healthcare industry's focus on value-based care, aiming to improve patient outcomes while reducing costs. The BVA diagnostic's ability to enhance the effectiveness of existing therapies could lead to shorter hospital stays and reduced readmission rates, key metrics in healthcare performance.
The ezBVA Lab service model is particularly attractive in the current healthcare environment, where capital expenditures are scrutinized. It allows hospitals to improve care quality without significant upfront costs. This could accelerate the adoption of advanced diagnostics in both large and small healthcare facilities, potentially reshaping the standard of care for heart failure patients across diverse healthcare settings.
1,000 Bed Comprehensive Medical Center Launches ezBVA Lab Program
Oak Ridge, TN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of its blood volume analysis (BVA) capabilities through its ezBVA Lab service. Daxor will partner with the hospital to provide lab processing of its patient tests, providing a rapid 24-hour testing service that is highly efficient for the hospital to implement.
The hospital is a leading 1,000+ bed comprehensive medical center in western Florida aiming to optimize heart failure treatment outcomes, improve patient and clinical experiences, and reduce associated costs. BVA facilitates optimal diagnosis of patient volume status, which is a cornerstone of both in-patient and out-patient heart failure care, enabling existing therapies to be far more effective for treating patients and reducing associated costs.
“Volume management is crucial in heart failure care,” said Michael Feldschuh, Daxor’s CEO and President. “Our BVA diagnostic delivers
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100™ (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What is Daxor's new partnership for its BVA-100™ Blood Volume Diagnostic?
How does Daxor's BVA-100™ diagnostic benefit heart failure treatment?
What is the ezBVA Lab service offered by Daxor (DXR)?
Is Daxor's ezBVA Lab service covered by insurance?
